INTELLIGENT DIAGNOSTICS FOR PERSONALIZED MEDICINE
Pierian Biosciences is focused on the development and delivery of innovative assays and analytical approaches in the rapidly changing fields of personalized medicine and translational science.
The advanced cytometric assay capabilities developed by Pierian Biosciences provide valuable information to aid pharmaceutical companies from early-stage drug development through clinical validation of new therapeutics. The aspiration is to improve patient outcomes and lower health care costs through the application of the ImmunoINTEL and ChemoINTEL platforms.
A comprehensive functional immuno-assay focused on intra-tumoral and peripheral “markers” of immune system activation and competence to guide the selection of the most appropriate immunotherapeutic. [MORE]
Focuses On Enhancements to Company’s Immunotherapy Assay
Pierian Biosciences will present a poster with new data on ImmunoINTEL, at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer, to be held November 7-11, 2018 at the Walter E. Washington Convention Center in Washington, D.C. The poster, “ImmunoINTEL, a flow cytometry based platform that identifies and quantifies the most critical cell subsets and related functional potential in dissociated solid tumors,”
Recent published results (AACR 2018 and NEJM) from the Merck KEYNOTE-189 trial in non-squamous non-small cell lung cancer (NSCLC) proved to be very exciting in the world of oncology. The study showed that patients treated with pembrolizumab (Keytruda™) plus chemotherapy had significantly longer overall survival (OS) and progression-free survival (PFS) compared with those who received chemotherapy alone, meeting both its primary endpoints.read more